Pricing Log in Create free account
Saturday 17 October 2026 Export SBFM’s income statement to Excel — free account

Sunshine Biopharma, Inc.

SBFM Healthcare Drug Manufacturers Specialty & Generic

Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024. In the quarter to June 2026, revenue fell 1.56%, EPS grew 70.5% and free cash flow grew 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.22 0.01 −4.35%
Market cap
$990.0K
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
4/9
Altman Z
−1.72
Beneish M
−2.96
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.99
Revenue 35.35
Net Income (5.83)
Free Cash Flow (5.54)
Net Debt (13.75)
Current Ratio 5.46 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.39) (negative: loss-making)
P/S ratio 0.01
P/B ratio 0.01
Past 5Y EPS Growth —
This Y EPS Growth 86.46% (at or above 15%: strong)
Next Y EPS Growth 79.49% (at or above 15%: strong)
Next Y revenue growth 1.22%
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of −0.1×; over the ten years it ranged from −55.3× in 2022 to 23,815× in 2020.
P/S against its own 10 years 2.37%
10-year low 10-year high
P/B against its own 10 years 3.31%
10-year low 10-year high
EV/FCF against its own 10 years 87.74%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 16 10 9 14
Receivables 3 4 3 4
Inventory 6 11 13 12
Other — — — 0
25 26 27 31
2023 2024 2025 Q'26
Payables 3 6 6 5
ST’ Debt — — — —
Other — — — —
6 6 6 6

Compound Annual Growth %

10y 5y 3y
Sales — 247.74% 102.91%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 2.13%

Revenue $m

Mar Jun Sep Dec Year
’26 8 9 — — —
’25 9 9 9 9 36
’24 8 9 8 10 35
’23 5 6 6 8 24
’22 0 0 0 4 4
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (2) (1) (1) (2) (5)
’24 (3) (5) (1) (3) (13)
’23 (2) (4) 0 (3) (9)
’22 (1) (1) (1) (2) (5)
’21 0 (1) (1) 0 (2)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (1) — — —
’25 (2) (2) (1) (2) (6)
’24 (4) (5) (2) (4) (15)
’23 (2) (4) 0 (3) (10)
’22 (1) (1) (1) (3) (6)
’21 0 (1) (1) 0 (2)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.50) (1.15) — — —
’25 (4.40) (3.90) (1.90) (4.60) (14.40)
’24 (20.02) (99.40) (9.40) 55.71 (73.20)
’23 (1.60k) (711.72) (501.14) (1.00k) (3.80k)
’22 (4.60k) (600.00) (1.60k) (30.00k) (35.20k)
’21 (56.38k) (24.07k) (31.77k) 16.99k (95.20k)
’20 (50.15) (118.57) (49.74) (54.37k) (54.59k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 3,333,333.25 3,316,666.75 500,000.00 24,000.00 5,200.00 60,000.00 12,400.00 4,100.00 21.06 11.60

Analyst estimates 2026–2028

Powerpack
High 62,500,000.00 46,666,668.00 29,166,666.00 2,400,000.00 3,778,000.00 1,256,000.00 310,000.00 28,000.00 5,820.00 39.00
People
People Employees 3 3 9 3 3 3 46 44 52 50
Revenue/emp, $m 0.00 0.00 0.00 0.01 0.02 0.08 0.09 0.55 0.67 0.73
Income, $m
Income, $m Revenue — — — 0 0 0 4 24 35 36
Gross margin, % 0.00 0.00 0.00 47.87 63.87 48.42 39.04 34.61 30.60 33.76
EBT (3) (1) (2) (1) (3) (12) (27) (4) (5) (6)
EBT margin, % 0.00 0.00 0.00 (5,109.48) (3,899.30) (5,445.05) (610.07) (17.06) (15.40) (16.40)
Net income (3) (1) (2) (2) (3) (12) (27) (5) (5) (6)
Depreciation 1 0 0 0 0 0 18 0 0 2
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 42.20 714.00 2,284.00 5,432.00 18,532.92 496.78 87.34
Earnings (164.60) (476.80) (14,153.54) (3,037.26) (54,590.02) (95,200.00) (35,200.00) (3,800.00) (73.20) (14.40)
Cash flow (14.82) (247.05) (2,564.00) (991.60) (6,573.00) (18,291.00) (6,560.50) (6,750.08) (178.42) (12.82)
Capex (0.16) (1.68) (94.50) (1.80) (12.00) 0.00 (381.25) (606.23) (28.20) (2.01)
Free cash flow (14.98) (248.73) (2,658.50) (993.40) (6,585.00) (18,291.00) (6,941.75) (7,356.31) (206.61) (14.84)
Book value (9.89) (260.64) (279.00) (1,470.80) (9,548.00) 2,117.00 27,034.50 16,313.38 334.77 55.42
Shares, m 0 0 0 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 853.08 87.96 102.32 2.74 0.30 0.06 0.14
P/B — — — 0.00 0.00 209.31 0.55 0.34 0.09 0.22
EV/Sales — — — 867.10 87.38 101.68 (1.84) (0.30) (0.16) (0.06)
EV/FCF — — — (37.06) (9.45) (12.68) 1.47 0.76 0.39 0.34
Cash, $m
Cash, $m Operating cash flow 0 (1) (1) 0 (1) (2) (5) (9) (13) (5)
Capex 0 0 0 0 0 — 0 (1) (2) (1)
Free cash flow 0 (1) (1) 0 (1) (2) (6) (10) (15) (6)
Balance, $m
Balance, $m Working capital 0 (1) 0 (1) 0 2 20 19 20 20
Total debt 0 0 0 1 1 2 1 — — —
Net debt 0 0 0 0 0 0 (22) (16) (10) (9)
Shareholders’ equity 0 (1) 0 (1) (1) 0 22 21 24 23
Returns, %
Returns, % ROA (948.00) (646.29) (307.13) (266.78) (486.90) (765.70) (170.09) (15.92) (17.73) (19.71)
ROIC 0.00 0.00 (589.22) 0.00 0.00 (2,293.33) 0.00 (60.85) (26.30) (27.97)
ROE 771.30 235.58 591.39 372.60 302.59 2,637.37 (246.06) (21.04) (22.97) (25.69)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Sunshine Biopharma, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AKAN Akanda Corp. $3.5M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
PRFX PainReform Ltd. $2.6M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
BTAIQ BioXcel Therapeutics, Inc. $2.3M — (loss-making) — (loss-making) +51.67% (above 0%: growing) n/m +51.51% (above 0%: growing) 87.91% (5,600.55%) Compare
IMCC IM Cannabis Corp. $2.2M — (loss-making) — (loss-making) −40.28% (below 0%: shrinking) n/m −266.81% (below 0%: shrinking) 19.83% (27.54%) Compare
NEPTF Neptune Wellness Solutions Inc. $1.6M — (loss-making) — (loss-making) −37.75% (below 0%: shrinking) n/m +53.44% (above 0%: growing) 13.62% (232.88%) Compare
PTPI Petros Pharmaceuticals, Inc. $1.0M — (loss-making) — (loss-making) +1,070.55% (above 0%: growing) n/m +71.27% (above 0%: growing) 73.82% 0.00% Compare
SBFM Sunshine Biopharma, Inc. $990.0K — (loss-making) — (loss-making) −1.56% (below 0%: shrinking) n/m +49.38% (above 0%: growing) 26.20% (17.41%)
LSDIF Lucy Scientific Discovery Inc. $900.0K — (loss-making) — — n/m −493.98% (below 0%: shrinking) 59.79% (8,891.75%) Compare
SXTC China SXT Pharmaceuticals, Inc. $710.0K — (loss-making) — (loss-making) −16.76% (below 0%: shrinking) +92.67% (above 0%: growing) −107.59% (below 0%: shrinking) 44.09% 0.00% Compare
Median of peers $1.9M — — −16.76% — −28.04% 31.96% (13.77%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Sunshine Biopharma, Inc. (SBFM) key facts

  • Strength: Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.
  • Sunshine Biopharma, Inc. (SBFM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SBFM traded at $0.22, a market capitalization of $990,000.00.
  • Return on equity was −25.7% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.72 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Sunshine Biopharma, Inc. (SBFM) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SBFM · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com